These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 39140001)

  • 1. Efficacy of Combination of Antiviral Therapy With Neutralizing Monoclonal Antibodies for Recurrent Persistent SARS-CoV-2 Pneumonia in Patients With Lymphoma.
    Gai X; Sun X; Liu B; Yan W; Sheng Z; Zhou Q; Sun Y
    Biomed Res Int; 2024; 2024():8182887. PubMed ID: 39140001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody.
    Maruyama S; Wada D; Kanayama S; Shimazu H; Miyano Y; Inoue A; Kashihara M; Okuda K; Saito F; Nakamori Y; Ishii K; Kuwagata Y
    BMC Infect Dis; 2024 Jul; 24(1):715. PubMed ID: 39039440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
    Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M
    Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection.
    Ito W; Fukumori T; Asaoka N; Imakita N; Nishimura T; Furukawa R; Nishihara Y; Fujikura H; Sekine T; Yamaguchi N; Hirata Y; Miyamoto S; Kanno T; Katano H; Suzuki T; Kasahara K
    J Infect Chemother; 2024 Jul; 30(7):659-663. PubMed ID: 38184107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma.
    Maruki T; Nomoto H; Iwamoto N; Yamamoto K; Kurokawa M; Iwatsuki-Horimoto K; Yamayoshi S; Suzuki Y; Kawaoka Y; Ohmagari N
    J Infect Chemother; 2024 Aug; 30(8):793-795. PubMed ID: 38242284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
    Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
    J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies.
    Hagihara M; Hayashi H; Nakashima S; Imai Y; Nakano H; Uchida T; Inoue M; Sakai-Tagawa Y; Ito M; Yamayoshi S; Iwatsuki-Horimoto K; Suzuki Y; Kawaoka Y
    Intern Med; 2024 Aug; 63(16):2283-2287. PubMed ID: 38171874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab.
    Aihara R; Umemura K; Katada Y; Nakagawa S; Kobayashi T; Hatano E; Date H; Nagao M; Terada T
    J Infect Chemother; 2024 Dec; 30(12):1222-1227. PubMed ID: 38777151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
    Mazzotta V; Mazzaferri F; Lanini S; Mirandola M; Cozzi Lepri A; Vergori A; Savoldi A; Santoro A; Maccarrone G; Mastrorosa I; Simonetti O; Zottis F; Nicastri E; Rosini G; Rovigo L; Tavernaro L; Sarmati L; Tascini C; Girardi E; Cattelan AM; Antinori A; Tacconelli E;
    J Infect; 2024 Nov; 89(5):106294. PubMed ID: 39343244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
    Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.
    Huygens S; GeurtsvanKessel C; Gharbharan A; Bogers S; Worp N; Boter M; Bax HI; Kampschreur LM; Hassing RJ; Fiets RB; Levenga H; Afonso PM; Koopmans M; Rijnders BJA; Oude Munnink BB
    Clin Infect Dis; 2024 Jun; 78(6):1514-1521. PubMed ID: 38445721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
    Pasquini Z; Toschi A; Casadei B; Pellegrini C; D'Abramo A; Vita S; Beccacece A; Bussini L; Chionsini MC; Dentale N; Cantiani A; Lazzarotto T; Bartoletti M; Nicastri E; Zinzani P; Giannella M; Viale P
    Hematol Oncol; 2023 Dec; 41(5):904-911. PubMed ID: 37452579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies.
    Lalle E; Mazzotta V; Sberna G; Fabeni L; Garbuglia AR; Mastrorosa I; D'Abramo A; Nicastri E; Girardi E; Antinori A; Maggi F; Bordi L
    Viruses; 2024 Jun; 16(7):. PubMed ID: 39066203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
    Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
    Front Immunol; 2021; 12():613502. PubMed ID: 33968017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
    Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
    mBio; 2020 May; 11(3):. PubMed ID: 32444382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
    In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review.
    Kinsella PM; Moso MA; Morrissey CO; Dendle C; Guy S; Bond K; Sasadeusz J; Slavin MA
    Transpl Infect Dis; 2024 Jun; 26(3):e14301. PubMed ID: 38809102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.